초록 ▼

This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, antioxidant or anti-inflammatory co

This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, antioxidant or anti-inflammatory compounds to the gastrointestinal tract after oral administration.

대표청구항 ▼

What is claimed is: 1. A pharmacological composition in a tablet or capsule comprising a proliposomal preparation, an enteric coating, and a protective coating in between the proliposomal preparation and the enteric coating, wherein the proliposomal preparation consists of at least one phospholipid

What is claimed is: 1. A pharmacological composition in a tablet or capsule comprising a proliposomal preparation, an enteric coating, and a protective coating in between the proliposomal preparation and the enteric coating, wherein the proliposomal preparation consists of at least one phospholipid, stearylamine, cholesterol, a polycyclic aromatic antioxidant or anti-inflammatory compound, and an optional particle lubricant, where the weight amount of stearylamine is less than the weight amount of cholesterol, and where the weight amount of cholesterol is less than the weight amount of phospholipid. 2. A pharmacological composition according to claim 1 wherein the polycyclic aromatic antioxidant or anti-inflammatory compound is cis-stilbene; trans-stilbene; 3-, 4-, or 4'-hydroxy, or (3,4')-or (4',5)-dihydroxy cis-stilbene; 3-, 4-, or 4'-hydroxy, or (3,4')-or (4',5)-dihydroxy trans-stilbene; carboxylated derivatives of cis-stilbene or trans-stilbene; halogenated derivatives of cis-stilbene or trans-stilbene; resveratrol (trans-3,5,4'-trihydroxystilbene); chrysin (5,7-dihydroxyflavone) or quercetin (3,3',4',5,7-pentahydroxyflavone), or biologically-active derivatives thereof. 3. A pharmacological composition according to claim 2 wherein the enteric coating is cellulose acetate phthalate or a poly(acrylate, methacrylate) copolymer. 4. A pharmacological composition according to claim 2 wherein the protective coating is hydroxypropyl methylcellulose, polyethylene glycol or ethylcellulose. 5. A pharmacological composition according to claim 1 wherein the protective coating further comprises a plasticizer. 6. A pharmacological composition according to claim 5 wherein the plasticizer is triethylcitrate or polyvinyl pyrrolidine. 7. A pharmacological composition according to claim 1 wherein the proliposomal composition consists of at least one phospholipid, stearylamine, cholesterol, a polycyclic aromatic antioxidant or anti-inflammatory compound, and a particle lubricant, wherein the particle lubricant is talc, lactose, corn starch, ethyl cellulose, fatty acids or salts thereof, agar, pectin, gelatin or acacia. 8. A pharmacological composition according to claim 2 wherein the polycyclic aromatic antioxidant or anti-inflammatory compound is resveratrol, quercetin or chrysin. 9. A pharmacological composition according to claim 1 wherein the phospholipid is a phosphatidylcholine, a phosphatidylethanolamine, sphingosine, ceramide, or a mixture thereof. 10. A pharmacological composition according to claim 9 wherein the phosphatidylcholine is distearylphosphatidylcholine, dimyristylphosphatidylcholine or a mixture thereof. 11. A method for increasing the bioavailability of a polycyclic, aromatic antioxidant or anti-inflammatory compound, said method comprising orally administering to an animal in need thereof a pharmaceutical preparation in a capsule or tablet comprising a proliposomal preparation, an enteric coating, and a protective coating in between the proliposomal preparation and the enteric coating, wherein the proliposomal preparation consists of at least one phospholipid, stearylamine, cholesterol, a polycyclic, aromatic antioxidant or anti-inflammatory compound, and an optional particle lubricant, where the weight amount of stearylamine is less than the weight amount of cholesterol, and where the weight amount of cholesterol is less than the weight amount of phospholipid. 12. A method according to claim 11 wherein the animal is a human. 13. A method according to claim 11 wherein the polycyclic aromatic antioxidant or anti-inflammatory compound is cis-stilbene; trans-stilbene; 3-, 4-, or 4'-hydroxy, or (3,4')-or (4',5)-dihydroxy cis-stilbene; 3-, 4-, or 4'-hydroxy, or (3,4')-or (4',5)-dihydroxy trans-stilbene; carboxylated derivatives of cis-stilbene or trans-stilbene; halogenated derivatives of cis-stilbene or trans-stilbene; resveratrol (trans-3,5,4'-trihydroxystilbene); chrysin (5,7-dibydroxyflavone) or quercetin (3,3',4',5,7-pentahydroxyflavone), or biologically-active derivatives thereof. 14. A method according to claim 13 wherein the polycyclic aromatic antioxidant or anti-inflammatory compound is resveratrol, quercetin or chrysin. 15. A method according to claim 11 wherein the enteric coating is cellulose acetate phthalate or a poly (acrylate, ruethacrylate) copolymer. 16. A method according to claim 11 wherein the protective coating is hydroxypropyl methylcellulose, polyethylene glycol or ethylcellulose. 17. A method according to claim 11 wherein the protective coating further comprises a plasticizer. 18. A method according to claim 17 wherein the plasticizer is triethylcitrate or polyvinyl pyrrolidine. 19. A method according to claim 11 wherein the proliposomal preparation consists of at least one phospholipid, stearylamine, cholesterol, a polycyclic, aromatic antioxidant or anti-inflammatory compound, and a particle lubricant, wherein the particle lubricant is talc, lactose, corn starch, ethyl cellulose, fatty acids or salts thereof, agar, pectin, gelatin or acacia. 20. A method according to claim 11 wherein the phospholipid a phosphatidylcholine, a phosphatidylethanolamine, sphingosine, ceramide, or a mixtures thereof. 21. A method according to claim 20 wherein the phosphatidylcholine is distearylphosphatidylcholine, dimyristylphosphatidylcholine or a mixture thereof. 22. A method of preventing coronary heart disease, myocardial infarction, ischemia, stroke, thrombosis, pulmonary embolism, or cancer, said method comprising administering a composition of claim 1 to human in need thereof. 23. A method for delivering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to the intestine or colon, said method comprising orally administering to an animal in need thereof a pharmaceutical preparation in a tablet comprising a proliposomal preparation, an enteric coating, and a protective coating in between the proliposomal preparation and the enteric coating, wherein the proliposomal preparation consists of at least one phospholipid, stearylamine, cholesterol, a polycyclic, aromatic, antioxidant or anti-inflammatory compound, and an optional particle lubricant, where the weight amount of stearylamine is less than the weight amount of cholesterol, and where the weight amount of cholesterol is less than the weight amount of phospholipid. 24. A method according to claim 23 wherein the animal is a human. 25. A method according to claim 23 wherein the polycyclic aromatic antioxidant or anti-inflammatory compound is cis-stilbene; trans-stilbene; 3-, 4-, or 4'-hydroxy, or (3,4')-or (4',5)-dihydroxy cis-stilbene; 3-, 4-, or 4'-hydroxy, or (3,4')-or (4',5)-dihydroxy trans-stilbene; carboxylated derivatives of cis-stilbene or trans-stilbene; halogenated derivatives of cis-stilbene or trans-stilbene; resveratrol (trans-3,5,4'-trihydroxystilbene); chrysin (5,7-dihydroxyflavone) or quercetin (3,3',4',5,7-pentahydroxyflavone), or biologically-active derivatives thereof. 26. A method according to claim 25 wherein the polycyclic aromatic antioxidant or anti-inflammatory compound is resveratrol, quercetin or chrysin. 27. A method according to claim 23 wherein the enteric coating is cellulose acetate phthalate or a poly(acrylate, methacrylate) copolymer. 28. A method according to claim 23 wherein the protective coating is hydroxypropyl methylcellulose, polyethylene glycol or ethylcellulose. 29. A method according to claim 23 wherein the protective coating further comprises a plasticizer. 30. A method according to claim 23 wherein the plasticizer is triethylcitrate or polyvinyl pyrrolidine. 31. A method according to claim 23 wherein the proliposomal preparation consists of at least one phospholipid, stearylamine, cholesterol, a polycyclic, aromatic, antioxidant or anti-inflammatory compound, and a particle lubricant, wherein the particle lubricant is talc, lactose, corn starch, ethyl cellulose, fatty acids or salts thereof, agar, pectin, gelatin or acacia. 32. A method according to claim 23 wherein the phospholipid is a phosphatidylcholine, a phosphatidylethanolamine, sphingosine, ceramide, or a mixture thereof. 33. A method according to claim 23 wherein the phosphatidylcholine is distearylphosphatidylcholine, dimyristylphosphatidylcholine or a mixture thereof.